Nektar Therapeutics (NKTR)

18.73 +0.29  +1.57% NASDAQ Apr 9, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/08/2020 17:00 EDT Misc Nektar Therapeutics Inc First Quarter Earnings Conference Call in 2020
05/08/2020 Earnings Nektar Therapeutics Inc First Quarter Earnings in 2020 Release
02/27/2020 17:00 EST Misc Nektar Therapeutics Inc Fourth Quarter Earnings Conference Call for 2019
02/27/2020 Earnings Nektar Therapeutics Inc Fourth Quarter Earnings Results for 2019
11/06/2019 17:00 EST Misc Nektar Therapeutics Inc Third Quarter Earnings Conference Call for 2019
11/06/2019 Earnings Nektar Therapeutics Inc Third Quarter Earnings for 2019 Release
08/08/2019 17:00 EDT Misc Nektar Therapeutics Inc Second Quarter Earnings Conference Call in 2019
08/08/2019 Earnings Nektar Therapeutics Inc Second Quarter Earnings in 2019 Release
06/12/2019 14:00 PDT Misc Nektar Therapeutics Inc Annual General Meeting in 2018
05/08/2019 17:00 EDT Misc Nektar Therapeutics Inc First Quarter Earnings Conference Call in 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.nektar.com
  • Investor Relations URL: http://ir.nektar.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: May. 08, 2020
  • Last Earnings Release: Feb. 27, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Top Fund Holders

Symbol Name Weighting
GOFFX Invesco Oppenheimer Global Opp R5 8.64%
XPH SPDR® S&P Pharmaceuticals ETF 4.45%
CNCR Loncar Cancer Immunotherapy ETF 3.73%
FBT First Trust NYSE Arca Biotech ETF 2.99%
PILL Direxion Daily Phrmctcl&MdclBl3XShrsETF 2.72%
POAGX PRIMECAP Odyssey Aggressive Growth 2.30%
FPHAX Fidelity® Select Pharmaceuticals Port 1.00%
BTEC Principal Healthcare Innovators ETF 0.98%
JKL iShares Morningstar Small-Cap Value ETF 0.72%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.